---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-25-000007"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T21:56:19.780678+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q4 net sales $748.8M (+2.3%), adj EPS $1.82; FY25 guidance $6.00-$6.20 EPS

## Summary
- Q4 organic net sales grew 3.3%, driven by Proprietary Products (+4.5%) led by self-injection devices.
- FY 2025 guidance: net sales $2.875B-$2.905B; adjusted EPS $6.00-$6.20 (vs. FY24 $6.75).
- Proprietary Products Q4 HVP sales were 74% of segment; Biologics unit had high-single-digit organic growth.
- FY 2024 free cash flow $276.4M, down 33.3%; $560.9M spent on share repurchases during year.
- CEO cited improving HVP trends in Biologics/Generics and growth from Annex 1 and GLP-1.

## SEC filing metadata
- accession: 0000105770-25-000007
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577025000007/0000105770-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577025000007/wst-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-25-000007
- JSON: https://secwatch.observer/filing/0000105770-25-000007.json
- Plain text: https://secwatch.observer/filing/0000105770-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.